Professional Documents
Culture Documents
Bibliografia
Bibliografia
BIBLIOGRAFÍA
1. Abrams L., Skee D., Natarajan J., et al. Pharmacokinetic overview of Ortho
Evra/ Evra. Fértil Steril 2002: 77(2 Suppl 2): 27-31
2. Aegidius K, Zwart JA, Hagen K, Schei B, Stovner LJ. The Head-HUNT Study.
Oral contraceptives and increased headache prevalence. NEUROLOGY
2006;66:349-353
3. Affandi B. Un análisis integrado del patrón de sangrado vaginal en estudios
clínicos del Implanón. Contraceptión 1998, 58: 99S-107S.
4. Ahmed T. El Estado de la Población Mundial. FNUPA. 2001:3-7
5. Alan Guttmacher Institute: Teenage Pregnancy: The problem that gasn't Gone
Away. New York, Alan Guttmacher Institute, 1981.
6. Alexander NJ. Future Contraceptives. Scientific American, 1995. Sept:137-140.
7. Archer D.F., Bigriff A., Smalwood G.H. Assesment of compliance with a weekly
contraceptive patch (ortho Evra/Evra) among North American women. Fertil
Steril 2002;77(2 Suppl 2): 3-13
8. Audet M.C., Moreau M., Koltun W. et al. Evaluation of contraceptive efficacy and
cycle control of a transdermal contraceptive pacth vs an oral contraceptive. A
randomized controlled trial. JAMA. 2001;285(18):2347-54
9. Bahamondes L, Nascimento JAA, Munuce MJ, Fazano F, Faúndes A. The in vitro
effect of levonorgestrel on the acrosome reaction of human spermatozoa from
fertile men. Contraception 2003; 68: 55-9.
10.Baird DT.Emergency contraception: how does it work? Reprod Biomed Online.
2009;18 Suppl 1:32-6.
11.Banks E, Berrington A, Casabonne D. Overview of the relationship between use
of progestogen-only contraceptives and bone mineral density. Br J Obstet
Gynecol 2001; 108: 1214-1221
12.Banks E, Berrington AQ, Casabonne D. Overview of the relationship between
use of progestogen-only contraceptives and bone mineral density. Br J Obstet
Gynecol 2001;108:1241-1221
13.Barrera P.A., Gómez P.I. “Implantes Subdérmicos Anticonceptivos no
absorbibles”. Revista Controversias en Ginecobstetricia. Vol 5(27): 5-20, 2000
14.Benno R. et als. Natural Family Planning. Am J Obstet and Gynecol. 1987,
157(4) :1082-1089.
15.Brown JB,Blakweek LF, Billings JJ. Natural Family Planning Am J Obstet Ginec,
1987, 157:1082-9.
16.Burkman R. Oral Contraceptives current status. Clin Obstet & Gynecol.2001;
44(1):62-72
17.Cancer CGoHFiB. Breast cancer and hormonal contraceptives. Collaborative
reanalysis of individual data on 53297 women with breast cancer and 100239
women without breast cancer from 54 epidemiological studies, Lancet 1996;
347:1713-1727
18.Canto De Cetina TE, Canto P, Lina MO. Effect of counselling to improve
compliance in Mexican women receiving depot medroxyprogesterone acetate.
Contraception 2001;63:143-146
19.Collaborative Review of Sterilization (CREST) study. New England Journal of
Medicine.2000 ;(343):1681–1687.
20.Conferencia Internacional sobre la Población y el Desarrollo. Programa de
Acción. El Cairo. Septiembre de 1994
1
A NTICONCEPCIÓN B ASADA EN E VIDENCIAS
2
A NTICONCEPCIÓN B ASADA EN E VIDENCIAS
3
A NTICONCEPCIÓN B ASADA EN E VIDENCIAS
4
A NTICONCEPCIÓN B ASADA EN E VIDENCIAS
5
A NTICONCEPCIÓN B ASADA EN E VIDENCIAS
6
A NTICONCEPCIÓN B ASADA EN E VIDENCIAS
135. Rahman M, Berenson AB. Predictors of higher bone mineral density loss and
use of depot medroxyprogesterone acetate. Obstet Gynecol. 2010;115(1):35-
40
136. Raine TR, Epstein LB, Harper CC, Brown BA, Boyer CB. Attitudes toward the
vaginal ring and transdermal patch among adolescents and young women. J
Adolesc Health. 2009 Sep;45(3):262-7.
137. Reglamento Técnico para el abordaje integral forense de la víctima en la
investigación del delito sexual -Instituto Nacional de Medicina Legal y Ciencias
Forenses-Establecimiento Público adscrito a la Fiscalía General de la Nación-
Noviembre de 2002
Reintroducing the IUD, Family Health International (FHI). 2005.
138. República de Colombia, LEY 28 DE 1932,(12 denoviembre)
139. República de Colombia.DECRETO 1972 DE 1933(1 de diciembre)
140. República de Colombia. LEY 45 DE 1936(21 de febrero),
141. República de Colombia. Reforma Constitucional de 1945.
142. República de Colombia. Plebiscito de 1954(3 de septiembre)
143. República de Colombia. Ley 54 de 1962
144. República de Colombia. Decreto 2820 de 1974(20 de diciembre)
145. República de Colombia. LEY 1 DE 1976(Enero 19)
146. República de Colombia. LEY 51 DE 1981(Junio 2)
147. República de Colombia. Decreto 1398 de 1990(3 de julio)
148. República de Colombia. Constitución Política de 1991
149. República de Colombia.Sentencia No. T-494 de 1992(17 de marzo)
150. República de Colombia. Ley 100 de 1993 (23 de diciembre)
151. República de Colombia. Ley 360 de 1997 (7 de febrero)
152. República de Colombia. Resolución 412 de 2000 (25 de febrero)
153. República de Colombia. Política Nacional de Salud Sexual y Reproductiva,
2003
154. República de Colombia. Ministerio de la Protección Social: Plan de choque
para la reducción de la mortalidad materna. 2004
155. República de Colombia. SENTENCIA C-355 DE 2006 (11 de mayo)
156. República de Colombia. LEY 1098 de 2006 (8 de noviembre)
157. República de Colombia. LEY 1146 de 2007 (10 de julio)
158. República de Colombia. Decreto 3039 de 2007 (10 de agosto)
159. República de Colombia RESOLUCION 0769 DE 2008 (3 de marzo)
160. Revisión del programa y desarrollo de estrategias en Población. Ayuda
de Memoria.FONDO DE POBLACION DE LAS NACIONES UNIDAS. 2004
161. Rosenbaum P, Schmidt W, Helmerhorst FM, Wutte W, Rossmanith W,
Freundl F, et al. Inhibition of ovulation by a novel progestogen (drospirenone)
alone or in combination with ethinylestradiol. Eur J Contracept Reprod Health
Care 2000;5:16-24
162. Rowlands S. Newer Progestogens. Journal of Family Planning and
Reproductive Health Care. 2003;29(1):13-16
163. Ruiz J, Gómez P.I., Early Postpartum IUD Insertion with Ring Forceps. Acta
Obst. Gynecol Scandinavica,1997(76)167.
164. Ruiz J, Gómez P.I., Minilaparotomy under local anesthesia for tubal
ligation, Acta Obst. Gynecol Scandinavica,1997(76)167.
165. Saleh WA, Burkman RT, Zacur HA, et al. A randomized trial of three oral
contraceptives; comparison of bleeding patterns by contraceptive types and
steroid levels. Am J Obstet Gynecol 1993;168(6 Pt 1):1740-45
166. Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L, Mestanza-Peralta
M, Lara-Reyes P, Seuc AH, et al. A trial of contraceptive methods in women
with systemic lupus erythematosus. New England Journal of Medicine, 2005;
353:2539–2549.
7
A NTICONCEPCIÓN B ASADA EN E VIDENCIAS
8
A NTICONCEPCIÓN B ASADA EN E VIDENCIAS
187. Van der Wijden C, Kleijnen J, Van den Berk T. Amenorrea de la lactancia
para la planificación familiar (Revisión Cochrane traducida). En: La Biblioteca
Cochrane Plus, número 2, 2007
188. Watts DH, Park J-G, Cohn SE, Yu S, Hitti J, Stek A, et al. Safety and
tolerability of depot medroxyprogesterone acetate among HIV-infected
women on antiretroviral therapy: ACTG A5093. Contraception, 2008; 77:84–
90.
189. Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-
Provera®): a highly effective contraceptive option with proven long-term
safety. Contraception.2003;68:75-87
190. Westhoff C, Jain JK, Milsom I, Ray A. Changes in weight with depot
medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL.
Contraception, 2007; 75:261–267.
191. WHO Statement on hormonal contraception and bone health, 2005.
Consultado en línea el 5 de febrero de 2010 en la página Web:
http://www.who.int/reproductive-health/family_planning/bone_health.html
192. WHO Collaborative study of cardiovascular disease and Steroid
Contraception. Cardiovascular Disease and use of oral and injectable
progestogen-only contraceptives and combined injectable contraceptives.
Results of an international, multicenter, case-control study. Contraception 1998
57: 314-324.
193. WHO collaborative study of Cardiovascular disease and Steroid Hormone
contraception. schaemich stroke and OC: Results of an international
Multicentre case-control study, Lancet 1996; 348:498-505
194. WHO collaborative study of Cardiovascular disease and Steroid Hormone
contraception. Haemorrhagic stroke, overall stroke risk and OC: Results of an
international Multicentre case-control study, Lancet 1996; 348:505-510
195. WHO. Department of Reproductive Health and Research. March 2002
196. WHO Department of Reproductive Health and Research and Johns Hopkins
Bloomberg School of Public Health/Center for Communications Programs, INFO
Project. Family Planning: A Global Handbook for Providers. Baltimore and
Geneva:CCP and WHO, 2007
197. Wrigth K. Por que las mujeres no se toman la píldora. Rev. Network.
Family Health Internacional. 2003;23(3):8-11
198. Yeung,W. The effects of levonorgestrel on various sperm functions.
Contraception 2002; 66 (6)
199. Zhou L, Xiao B. Emergency contraception with Multiload Cu-375 SL IUD: a
multicenter clinical trial Contraception. 2001;64(2):107-12.
200. Zipper JA, Tatum H, Metalic Cooper as an intrauterine contraceptive
proceeding of the Eighth Conference,International planned Parenthood
Federation, London, 1967,302-6.
201. Zipper J, Medel M, Goldsmith A, et al. The clinical efficacy of the repeated
transcervical instillation of quinacrine for female sterilization. Int J Gynaecol
Obstet. 1976;14:499–50
202. Zipper J, Trujillo V. 25 years of quinacrine sterilization experience in Chile:
review of 2,592 cases. Int J Gynaecol Obstet. 2003;83(suppl 2):S23–S29
203. Zurawin R, Ayensu-Coker L. Innovations in Contraception: A Review.
Clinical Obstetrics and Gynecology. 2007; 50(2): 425–4